Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

A local researcher and seasoned executives founded a company that will bring new medical technology to market.

Omega Therapeutics appointed Kaan Certel as chief executive officer of the Cambridge, Mass.-based biotechnology company. Certel, who has been Omega's chief business officer since May, will succeed ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...